Showing 1871-1880 of 4063 results for "".
- Kowa Submits IND Application to the FDA to Begin Phase 2 Study of Ripasudil Hydrochloride Hydratehttps://modernod.com/news/kowas-submits-ind-application-to-the-fda-to-begin-phase-2-study-of-ripasudil-hydrochloride-hydrate/2476842/Kowa, which has been developing Ripasudil Hydrochloride Hydrate, a Rho kinase inhibitor, for the indication of corneal endothelial diseases, submitted an investigational new drug (IND) application to the FDA on August 30, 2019 in order to commence a phase 2 clinical
- Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Phase 2 Clinical Trial in Japan Ahead of Schedulehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-the-netarsudil-phase-2-clinical-trial-in-japan-ahead-of-schedule/2479568/Aerie Pharmaceuticals announced that enrollment for its phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated. The first patients to enter this prospective, double-masked, multicenter, placebo-
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- Phase 1/2 Study Evaluating THR-317 for DME Meets Primary Safety Endpointhttps://modernod.com/news/data-from-phase-1-2-clinical-study-evaluating-thr-317-anti-plgf-for-dme-presented-at-2019-floretina-meeting/2476638/Oxurion NV announced that clinical-stage data from a phase 1/2 study evaluating its anti-placental growth factor candidate THR-317 for the treatment of diabetic macular edema (DME) were presented at the FLORetina 2019 meeting in Florence, Italy. THR-317 (anti-PlGF) is a recombinant humanized mono
- Allegro Ophthalmics Announces Positive Topline Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-announces-positive-topline-results-of-phase-2-study-evaluating-risuteganib-in-patients-with-intermediate-dry-amd/2476627/Allegro Ophthalmics announced positive topline results of its phase 2 study of risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD). The clinical trial met its primary endpoint with 48 percent of patients in the risuteganib arm gaining ≥ 8 letters of
- OptiKira Awarded Phase 2 SBIR Grant to Support Development of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/optikira-awarded-phase-2-sbir-grant-to-support-development-of-retinitis-pigmentosa-treatment/2476622/OptiKira announced that it was awarded a phase 2 Small Business Innovation Research (SBIR) grant to support continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa (RP). The $1.6M grant will be used to advance one or more of OptiKira’s mo
- GenSight Biologics Announces Positive Data for PIONEER Phase 1/2 Clinical Trial of GS030 for the Treatment of RPhttps://modernod.com/news/gensight-biologics-announces-positive-data-for-pioneer-phase-1-2-clinical-trial-of-gs030-for-the-treatment-of-rp/2476561/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its first safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, combining gene therapy and optogenetics for the treatment of retinitis pigmentosa. The DSMB confirmed the absence of an
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the